Litcius/Paper detail

Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study

Elie Rassy, Cécile Dalban, Émeline Colomba, Lisa Derosa, Carolina Alves Costa Silva, Sylvie Négrier, Christine Chevreau, Gwénaëlle Gravis, Stéphane Oudard, Brigitte Laguerre, Philippe Barthélémy, M. Gross Goupil, Lionnel Geoffrois, Frédéric Rolland, Antoine Thiery-Vuillemin, Florence Joly, Sylvain Ladoire, Florence Tantot, Bernard Escudier, Laurence Albigès

2022Clinical Genitourinary Cancer20 citationsDOI

Topics & Concepts

NivolumabMedicineRenal cell carcinomaConcomitantInternal medicineAdverse effectNephrectomyOncologyGastroenterologyCancerImmunotherapyKidneyCancer Immunotherapy and BiomarkersRenal cell carcinoma treatmentFerroptosis and cancer prognosis
Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study | Litcius